AAAAAA

   
Results: 1-25 | 26-50 | 51-56
Results: 1-25/56
VOROZOLE (RIVIZOR(TM)) - AN ACTIVE AND WELL TOLERATED NEW AROMATASE INHIBITOR FOR THE TREATMENT OF ADVANCED BREAST-CANCER PATIENTS WITH PRIOR TAMOXIFEN EXPOSURE
Authors: PARIDAENS R ROY JA NOOIJ M KLIJN J HOUSTON SJ BEEX LVAM VINHOLES J TOMIAK E VANVRECKEM A LANGENAEKEN C VANGLABBEKE M PICCART MJ
Citation: R. Paridaens et al., VOROZOLE (RIVIZOR(TM)) - AN ACTIVE AND WELL TOLERATED NEW AROMATASE INHIBITOR FOR THE TREATMENT OF ADVANCED BREAST-CANCER PATIENTS WITH PRIOR TAMOXIFEN EXPOSURE, Anti-cancer drugs, 9(1), 1998, pp. 29-35
FINAL RESULTS OF A RANDOMIZED PHASE-II STUDY OF THE EORTC SOFT-TISSUEAND BONE SARCOMA (STSBS) GROUP COMPARING 2 DIFFERENT IFOSFAMIDE (IF) REGIMENS IN CHEMOTHERAPY UNTREATED ADVANCED SOFT-TISSUE SARCOMA (STS) PATIENTS (PTS)
Authors: VANOOSTEROM AT KRZEMIENLECKI K NIELSEN OS JUDSON I MOURIDSEN HT SVANCAROVA L WOLL P SPOONER D HERMANS C VANGLABBEKE M VERWEIJ J
Citation: At. Vanoosterom et al., FINAL RESULTS OF A RANDOMIZED PHASE-II STUDY OF THE EORTC SOFT-TISSUEAND BONE SARCOMA (STSBS) GROUP COMPARING 2 DIFFERENT IFOSFAMIDE (IF) REGIMENS IN CHEMOTHERAPY UNTREATED ADVANCED SOFT-TISSUE SARCOMA (STS) PATIENTS (PTS), Annals of oncology, 9, 1998, pp. 552-552
PHASE-II RANDOMIZED STUDY COMPARING DOCETAXEL (T) TO DOXORUBICIN (D) IN PREVIOUSLY UNTREATED SOFT-TISSUE SARCOMAS (STS)
Authors: DIPAOLA ED JUDSON I LEE M RUKA W BUESA J COLEMAN R HERMANS C VANGLABBEKE M VERWEIJ J
Citation: Ed. Dipaola et al., PHASE-II RANDOMIZED STUDY COMPARING DOCETAXEL (T) TO DOXORUBICIN (D) IN PREVIOUSLY UNTREATED SOFT-TISSUE SARCOMAS (STS), Annals of oncology, 9, 1998, pp. 553-553
IS OBTENTION OF PARTIAL-RESPONSE (PR) IN FRONT-LINE CHEMOTHERAPY CRITICAL TO IMPROVE OUTCOME OF METASTATIC SOFT-TISSUE SARCOMA (MSTS) PATIENTS (PTS)
Authors: LECESNE A JUDSON J CROWTHER D SOMERS R TURSZ T KEIZER J VANHOESEL D BLAY Y FRISCH J VANGLABBEKE M VANOOSTEROM AT VERWEIJ J
Citation: A. Lecesne et al., IS OBTENTION OF PARTIAL-RESPONSE (PR) IN FRONT-LINE CHEMOTHERAPY CRITICAL TO IMPROVE OUTCOME OF METASTATIC SOFT-TISSUE SARCOMA (MSTS) PATIENTS (PTS), Annals of oncology, 9, 1998, pp. 556-556
A PHASE-II STUDY OF RALTITREXED (TOMUDEX) AS 2ND OR 3RD LINE TREATMENT FOR PATIENTS (PTS) WITH ADVANCED SOFT-TISSUE SARCOMAS (ASTS) REFRACTORY TO DOXORUBICIN CONTAINING REGIMENS
Authors: BLAY JY JUDSON I RODENHUIS S HERMANS C SMITH M VANGLABBEKE M VERWEIJ J
Citation: Jy. Blay et al., A PHASE-II STUDY OF RALTITREXED (TOMUDEX) AS 2ND OR 3RD LINE TREATMENT FOR PATIENTS (PTS) WITH ADVANCED SOFT-TISSUE SARCOMAS (ASTS) REFRACTORY TO DOXORUBICIN CONTAINING REGIMENS, Annals of oncology, 9, 1998, pp. 566-566
EVALUATION OF RESPONSE TO TREATMENT IN SOLID TUMORS - CAN THE METHODOLOGY BE HARMONIZED AND SIMPLIFIED
Authors: THERASSE P EISENHAUER E WANDERS J VERWEIJ J VANGLABBEKE M VANOOSTEROM AT KAPLAN RS CHRISTIAN MC GWYTHER S ARBUCK SG
Citation: P. Therasse et al., EVALUATION OF RESPONSE TO TREATMENT IN SOLID TUMORS - CAN THE METHODOLOGY BE HARMONIZED AND SIMPLIFIED, Annals of oncology, 9, 1998, pp. 66-66
AN EORTC-ECSG PHASE-II STUDY OF VINORELBINE IN PATIENTS WITH RECURRENT AND OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK/
Authors: DEGARDIN M OLIVEIRA J GEOFFROIS L ROLLAND F ARMAND JP BASTIT P CHAUVERGNE J FARGEOT P VANGLABBEKE M LENTZ MA TRESCA P BOUDILLET J FUMOLEAU P CAPPELAERE P
Citation: M. Degardin et al., AN EORTC-ECSG PHASE-II STUDY OF VINORELBINE IN PATIENTS WITH RECURRENT AND OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK/, Annals of oncology, 9(10), 1998, pp. 1103-1107
CHOP IS THE STANDARD REGIMEN IN PATIENTS GREATER-THAN-OR-EQUAL-TO-70 YEARS OF AGE WITH INTERMEDIATE-GRADE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA - RESULTS OF A RANDOMIZED STUDY OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER LYMPHOMA COOPERATIVE STUDY-GROUP
Authors: TIRELLI U ERRANTE D VANGLABBEKE M TEODOROVIC I KLUINNELEMANS JC THOMAS J BRON D ROSTI G SOMERS R ZAGONEL V NOORDIJK EM
Citation: U. Tirelli et al., CHOP IS THE STANDARD REGIMEN IN PATIENTS GREATER-THAN-OR-EQUAL-TO-70 YEARS OF AGE WITH INTERMEDIATE-GRADE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA - RESULTS OF A RANDOMIZED STUDY OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER LYMPHOMA COOPERATIVE STUDY-GROUP, Journal of clinical oncology, 16(1), 1998, pp. 27-34
MAINTENANCE OF REMISSION WITH HUMAN RECOMBINANT INTERFERON ALFA-2A INPATIENTS WITH STAGE-III AND STAGE-IV LOW-GRADE MALIGNANT NON-HODGKINS-LYMPHOMA
Authors: HAGENBEEK A CARDE P MEERWALDT JH SOMERS R THOMAS J DEBOCK R RAEMAEKERS JMM VANHOOF A DEWOLFPEETERS C VANGLABBEKE M
Citation: A. Hagenbeek et al., MAINTENANCE OF REMISSION WITH HUMAN RECOMBINANT INTERFERON ALFA-2A INPATIENTS WITH STAGE-III AND STAGE-IV LOW-GRADE MALIGNANT NON-HODGKINS-LYMPHOMA, Journal of clinical oncology, 16(1), 1998, pp. 41-47
AGE HAS NO IMPACT ON ACUTE AND LATE TOXICITY OF CURATIVE THORACIC RADIOTHERAPY
Authors: PIGNON T GREGOR A KONING CS ROUSSEL A VANGLABBEKE M SCALLIET P
Citation: T. Pignon et al., AGE HAS NO IMPACT ON ACUTE AND LATE TOXICITY OF CURATIVE THORACIC RADIOTHERAPY, Radiotherapy and oncology, 46(3), 1998, pp. 239-248
EORTC-IDBBC (INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER) - 5 YEARSOF EUROPEAN COLLABORATION IN NEW DRUG DEVELOPMENT FOR BREAST-CANCER
Authors: AWADA A VANVRECKEM A PARIDAENS R BRUNING PF KLIJN J TOMIAK E VINHOLES J ROY JA KUSENDA Z BOES GH VANGLABBEKE M PICCART MJ
Citation: A. Awada et al., EORTC-IDBBC (INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER) - 5 YEARSOF EUROPEAN COLLABORATION IN NEW DRUG DEVELOPMENT FOR BREAST-CANCER, European journal of cancer, 33(8), 1997, pp. 1173-1176
NEW RADIOTHERAPY FRACTIONATION SCHEMES IN HEAD AND NECK CANCERS - THEEORTC TRIALS - A BENCHMARK
Authors: HORIOT JC BONTEMPS P BEGG AC LEFUR R VANDENBOGAERT W BOLLA M NGUYEN T VANDENWEIJNGAERT D BERNIER J LUSINCHI A STUSCHKE M LOPEZTORRECILLA D JANCAR B COLLETTE L VANGLABBEKE M PIERART M
Citation: Jc. Horiot et al., NEW RADIOTHERAPY FRACTIONATION SCHEMES IN HEAD AND NECK CANCERS - THEEORTC TRIALS - A BENCHMARK, European journal of cancer, 33, 1997, pp. 591-591
NEOADJUVANT CHEMOTHERAPY IN ADULT SOFT-TISSUE SARCOMA - EORTC PROTOCOL-62847
Authors: GORTZAK E AZARELLI A SANTORO A EZZAT A BUESA J VANGLABBEKE M KIRCKPATRICK A VERWEIJ J
Citation: E. Gortzak et al., NEOADJUVANT CHEMOTHERAPY IN ADULT SOFT-TISSUE SARCOMA - EORTC PROTOCOL-62847, European journal of cancer, 33, 1997, pp. 616-616
PHASE-II STUDY OF VINORELBINE (NVB) IN PATIENTS WITH METASTATIC AND OR RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)/
Authors: DEGARDIN M BASTIT P ROLLAND F ARMAND JP CHEVALLIER B VANGLABBEKE M BOUDILLET J TRESCA P
Citation: M. Degardin et al., PHASE-II STUDY OF VINORELBINE (NVB) IN PATIENTS WITH METASTATIC AND OR RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)/, European journal of cancer, 33, 1997, pp. 843-843
ETOPOSIDE IN MALIGNANT PLEURAL MESOTHELIOMA - 2 PHASE-II TRIALS OF THE EORTC LUNG-CANCER COOPERATIVE GROUP
Authors: SAHMOUD T POSTMUS PE VANPOTTELSBERGHE C MATTSON K TAMMILEHTO L SPLINTER TAW PLANTING AST SUTEDJA T VANPAWEL J VANZANDWIJK N BAAS P ROOZENDAAL KJ SCHRIJVER M KIRKPATRICK A VANGLABBEKE M ARDIZZONI A GIACCONE G
Citation: T. Sahmoud et al., ETOPOSIDE IN MALIGNANT PLEURAL MESOTHELIOMA - 2 PHASE-II TRIALS OF THE EORTC LUNG-CANCER COOPERATIVE GROUP, European journal of cancer, 33(13), 1997, pp. 2211-2215
PREDICTORS OF RESPONSE TO SUBSEQUENT CHEMOTHERAPY IN PLATINUM PRETREATED OVARIAN-CANCER - A MULTIVARIATE-ANALYSIS OF 704 PATIENTS
Authors: EISENHAUER EA VERMORKEN JB VANGLABBEKE M
Citation: Ea. Eisenhauer et al., PREDICTORS OF RESPONSE TO SUBSEQUENT CHEMOTHERAPY IN PLATINUM PRETREATED OVARIAN-CANCER - A MULTIVARIATE-ANALYSIS OF 704 PATIENTS, Annals of oncology, 8(10), 1997, pp. 963-968
CORTICOSTEROIDS SIGNIFICANTLY DELAY THE ONSET OF DOCETAXEL-INDUCED FLUID RETENTION - FINAL RESULTS OF A RANDOMIZED STUDY OF THE -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER
Authors: PICCART MJ KLIJN J PARIDAENS R NOOIJ M MAURIAC L COLEMAN R BONTENBAL M AWADA A SELLESLAGS J VANVRECKEM A VANGLABBEKE M
Citation: Mj. Piccart et al., CORTICOSTEROIDS SIGNIFICANTLY DELAY THE ONSET OF DOCETAXEL-INDUCED FLUID RETENTION - FINAL RESULTS OF A RANDOMIZED STUDY OF THE -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER, Journal of clinical oncology, 15(9), 1997, pp. 3149-3155
CONCOMITANT RADIOTHERAPY AND CHEMOTHERAPY IS SUPERIOR TO RADIOTHERAPYALONE IN THE TREATMENT OF LOCALLY ADVANCED ANAL CANCER - RESULTS OF APHASE-III RANDOMIZED TRIAL OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER RADIOTHERAPY AND GASTROINTESTINAL COOPERATIVE GROUPS
Authors: BARTELINK H ROELOFSEN F ESCHWEGE F ROUGIER P BOSSET JF GONZALEZ DG PEIFFERT D VANGLABBEKE M PIERART M
Citation: H. Bartelink et al., CONCOMITANT RADIOTHERAPY AND CHEMOTHERAPY IS SUPERIOR TO RADIOTHERAPYALONE IN THE TREATMENT OF LOCALLY ADVANCED ANAL CANCER - RESULTS OF APHASE-III RANDOMIZED TRIAL OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER RADIOTHERAPY AND GASTROINTESTINAL COOPERATIVE GROUPS, Journal of clinical oncology, 15(5), 1997, pp. 2040-2049
AGE IS NOT A LIMITING FACTOR FOR RADICAL RADIOTHERAPY IN PELVIC MALIGNANCIES
Authors: PIGNON T HORIOT JC BOLLA M VANPOPPEL H BARTELINK H ROELOFSEN F PENE F GERARD A EINHORN N NGUYEN TD VANGLABBEKE M SCALLIET P
Citation: T. Pignon et al., AGE IS NOT A LIMITING FACTOR FOR RADICAL RADIOTHERAPY IN PELVIC MALIGNANCIES, Radiotherapy and oncology, 42(2), 1997, pp. 107-120
RANDOMIZED TRIAL OF 2 REGIMENS OF CHEMOTHERAPY IN OPERABLE OSTEOSARCOMA - A STUDY OF THE EUROPEAN OSTEOSARCOMA INTERGROUP
Authors: SOUHAMI RL CRAFT AW VANDEREIJKEN JW NOOIJ M SPOONER D BRAMWELL VHC WIERZBICKI R MALCOLM AJ KIRKPATRICK A USCINSKA BM VANGLABBEKE M MACHIN D
Citation: Rl. Souhami et al., RANDOMIZED TRIAL OF 2 REGIMENS OF CHEMOTHERAPY IN OPERABLE OSTEOSARCOMA - A STUDY OF THE EUROPEAN OSTEOSARCOMA INTERGROUP, Lancet, 350(9082), 1997, pp. 911-917
PHASE-II STUDIES ON PROSTATE-CANCER
Authors: SCHRODER FH NORMING U BLUMENSTEIN BA BUSCH C VANGLABBEKE M HOISAETER PA JOHANSSON JE TRIBUKAIT B
Citation: Fh. Schroder et al., PHASE-II STUDIES ON PROSTATE-CANCER, Urology, 49(4A), 1997, pp. 3-14
FOTEMUSTINE IN PATIENTS WITH ADVANCED GASTRIC-CANCER, A PHASE-II TRIAL FROM THE EORTC-GITCCG (EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER, GASTROINTESTINAL-TRACT CANCER COOPERATIVE GROUP)
Authors: ROUGIER P VANPOTTELSBERGHE C KOK T PAILLOT B WAGENER T DEGREVE J FABRI MC GERARD B VANGLABBEKE M BLEIBERG H
Citation: P. Rougier et al., FOTEMUSTINE IN PATIENTS WITH ADVANCED GASTRIC-CANCER, A PHASE-II TRIAL FROM THE EORTC-GITCCG (EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER, GASTROINTESTINAL-TRACT CANCER COOPERATIVE GROUP), European journal of cancer, 32A(8), 1996, pp. 1432-1433
NO AGE LIMIT FOR RADICAL RADIOTHERAPY IN HEAD AND NECK TUMORS
Authors: PIGNON T HORIOT JC VANDENBOGAERT W VANGLABBEKE M SCALLIET P
Citation: T. Pignon et al., NO AGE LIMIT FOR RADICAL RADIOTHERAPY IN HEAD AND NECK TUMORS, European journal of cancer, 32A(12), 1996, pp. 2075-2081
ORAL IFOSFAMIDE MESNA VERSUS INTRAVENOUS IFOSFAMIDE/MESNA IN NON-SMALL-CELL LUNG-CANCER - A RANDOMIZED PHASE-II TRIAL OF THE EORTC LUNG-CANCER COOPERATIVE GROUP/
Authors: MANEGOLD C DRINGS P PAWINSKI A LENTZ MA VANGLABBEKE M VANZANDWIJK N BACHMANN P SCHNAARS Y SKACEL Z ZATLOUKAL P DOLENSKY J JACKEVICIUS A PETRUZELKA L GIACCONE G
Citation: C. Manegold et al., ORAL IFOSFAMIDE MESNA VERSUS INTRAVENOUS IFOSFAMIDE/MESNA IN NON-SMALL-CELL LUNG-CANCER - A RANDOMIZED PHASE-II TRIAL OF THE EORTC LUNG-CANCER COOPERATIVE GROUP/, Annals of oncology, 7(6), 1996, pp. 637-639
PHASE-II TRIAL OF VINORELBINE IN METASTATIC SQUAMOUS-CELL ESOPHAGEAL-CARCINOMA
Authors: CONROY T ETIENNE PL ADENIS A WAGENER DJT PAILLOT B FRANCOIS E BEDENNE L JACOB JH SEITZ JF BLEIBERG H VANPOTTELSBERGHE C VANGLABBEKE M DELGADO FM MERLE S WILS J
Citation: T. Conroy et al., PHASE-II TRIAL OF VINORELBINE IN METASTATIC SQUAMOUS-CELL ESOPHAGEAL-CARCINOMA, Journal of clinical oncology, 14(1), 1996, pp. 164-170
Risultati: 1-25 | 26-50 | 51-56